IR@PKUHSC  > 北京大学第二临床医学院  > 血液科
学科主题临床医学
The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission
Huang, Xiao-Jun; Zhu, Hong-Hu; Chang, Ying-Jun; Xu, Lan-Ping; Liu, Dai-Hong; Zhang, Xiao-Hui; Jiang, Bin; Jiang, Qian; Jiang, Hao; Chen, Yu-Hong; Chen, Huan; Han, Wei; Liu, Kai-Yan; Wang, Yu
刊名BLOOD
2012-06-07
DOI10.1182/blood-2011-11-389809
119期:23页:5584-5590
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Hematology
研究领域[WOS]Hematology
关键词[WOS]HLA-MISMATCHED/HAPLOIDENTICAL BLOOD ; BONE-MARROW-TRANSPLANTATION ; COMORBIDITY INDEX ; ADULTS ; DONOR ; OUTCOMES ; TRIAL ; DIAGNOSIS ; SURVIVAL ; RELAPSE
英文摘要

We report the results of a prospective, patient self-selected study evaluating whether haploidentical related donor stem cell transplantation (HRD-HSCT) is superior to chemotherapy alone as postremission treatment for patients with intermediate-or high-risk acute myeloid leukemia (AML) in first complete remission (CR1). Among totally 419 newly diagnosed AML patients, 132 patients with intermediate-and high-risk cytogenetics achieved CR1 and received chemotherapy alone (n = 74) or HSCT (n = 58) as postremission treatment. The cumulative incidence of relapse at 4 years was 37.5% +/- 4.5%. Overall survival (OS) and disease-free survival (DFS) at 4 years were 64.5% +/- 5.1% and 55.6% +/- 5.0%, respectively. The cumulative incident of relapse for the HRD-HSCT group was significantly lower than that for the chemotherapy-alone group (12.0% +/- 4.6% vs 57.8% +/- 6.2%, respectively; P < .0001). HRD-HSCT resulted in superior survival compared with chemotherapy alone (4-year DFS, 73.1% +/- 7.1% vs 44.2% +/- 6.2%, respectively; P < .0001; 4-year OS, 77.5% +/- 7.1% vs 54.7% +/- 6.3%, respectively; P = .001). Multivariate analysis revealed postremission treatment (HRD-HSCT vs chemotherapy) and high WBC counts at diagnosis as independent risk factors affecting relapse, DFS, and OS. Our results suggest that HRD-HSCT is superior to chemotherapy alone as postremission treatment for AML. (Blood. 2012;119(23):5584-5590)

语种英语
WOS记录号WOS:000307391400032
项目编号2011AA020105 ; 30971292 ; 30800485 ; 2008B05
资助机构Hi-Tech Research and Development Program of China ; National Natural Science Foundation of China ; Beijing Novel program
引用统计
被引频次:61[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/54122
专题北京大学第二临床医学院_血液科
作者单位Peking Univ, Peoples Hosp, Inst Hematol, Beijing Key Lab Hematopolet Stem Cell Transplant, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Huang, Xiao-Jun,Zhu, Hong-Hu,Chang, Ying-Jun,et al. The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission[J]. BLOOD,2012,119(23):5584-5590.
APA Huang, Xiao-Jun.,Zhu, Hong-Hu.,Chang, Ying-Jun.,Xu, Lan-Ping.,Liu, Dai-Hong.,...&Wang, Yu.(2012).The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission.BLOOD,119(23),5584-5590.
MLA Huang, Xiao-Jun,et al."The superiority of haploidentical related stem cell transplantation over chemotherapy alone as postremission treatment for patients with intermediate- or high-risk acute myeloid leukemia in first complete remission".BLOOD 119.23(2012):5584-5590.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Huang, Xiao-Jun]的文章
[Zhu, Hong-Hu]的文章
[Chang, Ying-Jun]的文章
百度学术
百度学术中相似的文章
[Huang, Xiao-Jun]的文章
[Zhu, Hong-Hu]的文章
[Chang, Ying-Jun]的文章
必应学术
必应学术中相似的文章
[Huang, Xiao-Jun]的文章
[Zhu, Hong-Hu]的文章
[Chang, Ying-Jun]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。